Park Avenue Securities LLC Has $505,000 Holdings in Align Technology, Inc. $ALGN

Park Avenue Securities LLC lifted its stake in shares of Align Technology, Inc. (NASDAQ:ALGN) by 11.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,668 shares of the medical equipment provider’s stock after buying an additional 269 shares during the period. Park Avenue Securities LLC’s holdings in Align Technology were worth $505,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALGN. Redmond Asset Management LLC lifted its position in shares of Align Technology by 2.0% during the 1st quarter. Redmond Asset Management LLC now owns 2,769 shares of the medical equipment provider’s stock worth $440,000 after buying an additional 54 shares in the last quarter. Horizon Investments LLC increased its stake in shares of Align Technology by 6.2% during the 1st quarter. Horizon Investments LLC now owns 1,018 shares of the medical equipment provider’s stock worth $162,000 after purchasing an additional 59 shares during the last quarter. Washington Trust Advisors Inc. increased its stake in shares of Align Technology by 5.2% during the 1st quarter. Washington Trust Advisors Inc. now owns 1,205 shares of the medical equipment provider’s stock worth $191,000 after purchasing an additional 60 shares during the last quarter. Covestor Ltd increased its stake in shares of Align Technology by 18.8% during the 1st quarter. Covestor Ltd now owns 493 shares of the medical equipment provider’s stock worth $78,000 after purchasing an additional 78 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its stake in shares of Align Technology by 42.2% during the 2nd quarter. Farther Finance Advisors LLC now owns 310 shares of the medical equipment provider’s stock worth $59,000 after purchasing an additional 92 shares during the last quarter. 88.43% of the stock is currently owned by institutional investors and hedge funds.

Align Technology Price Performance

ALGN opened at $126.37 on Tuesday. The company has a fifty day moving average price of $146.05 and a 200-day moving average price of $166.78. The firm has a market capitalization of $9.16 billion, a P/E ratio of 21.31, a price-to-earnings-growth ratio of 1.42 and a beta of 1.65. Align Technology, Inc. has a one year low of $122.00 and a one year high of $256.22.

Align Technology (NASDAQ:ALGN) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.57 by ($0.08). Align Technology had a return on equity of 13.36% and a net margin of 11.04%.The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter last year, the firm posted $2.41 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. Align Technology has set its Q3 2025 guidance at EPS. On average, analysts expect that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Align Technology announced that its board has authorized a stock repurchase program on Tuesday, August 5th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Morgan Stanley restated an “equal weight” rating and set a $154.00 price target (down previously from $249.00) on shares of Align Technology in a research note on Thursday, July 31st. Mizuho set a $210.00 price target on shares of Align Technology in a research note on Thursday, July 31st. Evercore ISI raised their price target on shares of Align Technology from $200.00 to $220.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 9th. Wells Fargo & Company decreased their price target on shares of Align Technology from $246.00 to $199.00 and set an “overweight” rating for the company in a research note on Thursday, July 31st. Finally, Piper Sandler decreased their price target on shares of Align Technology from $250.00 to $190.00 and set an “overweight” rating for the company in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $215.00.

Insider Transactions at Align Technology

In related news, CEO Joseph M. Hogan bought 7,576 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was bought at an average cost of $131.49 per share, for a total transaction of $996,168.24. Following the completion of the transaction, the chief executive officer owned 184,945 shares of the company’s stock, valued at approximately $24,318,418.05. The trade was a 4.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.66% of the company’s stock.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.